Linked Life Data

11116050

Source:http://linkedlifedata.com/resource/pubmed/id/11116050

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2000-12-20
pubmed:abstractText
It is unclear whether the previous in vitro evidence of a link between angiotensin II (Ang II) and growth factor receptors can apply to the in vivo situation. In this study, we examined vascular platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) receptor activation in stroke-prone spontaneously hypertensive rats (SHRSP) and the role of Ang II. Tyrosyl phosphorylation of the growth factor receptors was determined by Western blot analysis coupled with immunoprecipitation. Tyrosyl phosphorylation of the aortic PDGF beta-receptor, but not the EGF receptor, was chronically increased in SHRSP with hypertension, compared with normotensive rats, being accompanied by increased extracellular signal-regulated kinase (ERK) activity. Treatment of SHRSP with ACE inhibitors (perindopril or enalapril) significantly reduced aortic PDGF beta-receptor tyrosyl phosphorylation and ERK activity, whereas treatment with hydralazine failed to reduce these activities. Therefore, these aortic changes in SHRSP were mediated by Ang II in response to vascular ACE. Ang II was infused into rats to examine the effects on aortic growth factor receptors. Chronic Ang II infusion, via the angiotensin type 1 receptor, significantly increased activation of the aortic PDGF beta-receptor but not the EGF receptor. Thus, the aortic PDGF beta-receptor, activated by ACE-mediated Ang II, seems to be responsible for vascular remodeling in hypertensive rats.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1524-4636
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2539-45
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:11116050-Angiotensin II, pubmed-meshheading:11116050-Angiotensin-Converting Enzyme Inhibitors, pubmed-meshheading:11116050-Animals, pubmed-meshheading:11116050-Aorta, Thoracic, pubmed-meshheading:11116050-Blood Pressure, pubmed-meshheading:11116050-Disease Models, Animal, pubmed-meshheading:11116050-Enalapril, pubmed-meshheading:11116050-Hypertension, pubmed-meshheading:11116050-Infusions, Intravenous, pubmed-meshheading:11116050-Male, pubmed-meshheading:11116050-Mitogen-Activated Protein Kinases, pubmed-meshheading:11116050-Peptidyl-Dipeptidase A, pubmed-meshheading:11116050-Perindopril, pubmed-meshheading:11116050-Phosphorylation, pubmed-meshheading:11116050-Rats, pubmed-meshheading:11116050-Rats, Inbred SHR, pubmed-meshheading:11116050-Receptor, Epidermal Growth Factor, pubmed-meshheading:11116050-Receptors, Platelet-Derived Growth Factor
pubmed:year
2000
pubmed:articleTitle
In vivo activation of rat aortic platelet-derived growth factor and epidermal growth factor receptors by angiotensin II and hypertension.
pubmed:affiliation
Department of Pharmacology, Osaka City University Medical School, Osaka, Japan. kims@med.osaka-cu.ac.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't